/
1 1   TEAP/MTOC Addendum Report 1 1   TEAP/MTOC Addendum Report

1 1 TEAP/MTOC Addendum Report - PowerPoint Presentation

SunshineSmile
SunshineSmile . @SunshineSmile
Follow
346 views
Uploaded On 2022-08-02

1 1 TEAP/MTOC Addendum Report - PPT Presentation

Review of Additional Information Essential Use Nomination from China 2013 M o n t r e a l P r o t o c o l M O P 2 3 2 1 2 5 N o v e m b e r 2 0 1 1 B a l i 2 China EUN 2013 ID: 932522

china mdis tcm 2013 mdis china 2013 tcm cfc mtoc information additional cfcs review asthma nominated eun nomination studies

Share:

Link:

Embed:

Download Presentation from below link

Download Presentation The PPT/PDF document "1 1 TEAP/MTOC Addendum Report" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.


Presentation Transcript

Slide1

1

1

TEAP/MTOC Addendum ReportReview of Additional InformationEssential Use Nomination from China 2013

M o n t r e a l P r o t o c o l

M O P

-

2 3 , 2 1 - 2 5 N o v e m b e r 2

0 1 1,

B a l

i

Slide2

2

China EUN 2013: Review of additional information (1)

Bilateral discussions during 32nd

OEWG Meeting between China delegation and attending MTOC co-chairsAdditional information supporting China’s nomination provided 31st August for MTOC review, pertaining only to CFC MDIs containing Traditional Chinese Medicines (TCMs) as active ingredientsChina nomination includes 9 tonnes CFCs to manufacture MDIs containing datura metel extract/clenbuterol, and ephedra/gingko/sophoroflavescens/radix scutellariaeMTOC assessment provided in an Addendum Report published early October

M o n t r e a l P r o t o c o l

M O P

-

2 4 , 1 2 - 1 6 N o v e m b e r 2

0 1

2, G e n e v a

Slide3

3

China EUN 2013: Review of additional information (2)

Affordable oral and injectable TCM treatments for asthma have been

available in China for a long time.MTOC sought evidence to test whether TCM CFC MDIs show improved efficacy compared with other TCM asthma treatment forms, such as oral or injectable. Additional information was provided from clinical studies of the effectiveness of the nominated TCM CFC MDIs as anti-asthmatic drugs.Studies for both TCM CFC MDIs indicated the inhalers to be more effective as anti-asthma treatments than the controls selected for use in the studies.

M o n t r e a l P r o t o c o l

M O P

-

2 4 , 1 2 - 1 6 N o v e m b e r 2

0 1

2, G e n e v a

Slide4

4

China EUN 2013: Review of additional information (3)

Traditional Chinese medicine has its own rationale that may not be subjected to the same scientific discipline as modern medicine

.Evidence has not been provided that demonstrates the improved efficacy of TCM CFC MDIs compared with other forms of TCMs for asthma.MTOC does not consider CFCs for this use to be essential under Decision IV/25 due to the availability of suitable alternatives, and is unable to recommend the nominated CFCs for these products.For 2013, China may wish to consider allocating CFCs for these products from within its authorised quantity to allow time for patient transition from TCM CFC MDIs to alternatives.M o n t r e a l P r o t o c o l

M O P

-

2 4 , 1 2 - 1 6 N o v e m b e r 2

0 1

2, G e n e v a

Slide5

5

Essential

Uses Recommendations:

Summary

for Metered Dose Inhalers (MDIs)

For Parties nominating CFCs for MDIs:

Authorized for 2012;

Nominated

(Recommended)

for

2013 in metric

tonnes

.

Party

2012

Authorized

2013

Nominated

(Recommended)

Bangladesh

40.35

-

China

532.04

446.52

(386.82)

Pakistan

24.1

-

Russian Fed.

212.0

250

(212.0)

M o n t r e a l P r o t o c o l

M O P

-

2 4 , 1 2 - 1 6 N o v e m b e r 2

0 1

2, G e n e v a